Overview
Lunit is a global leader in AI-based medical solutions, specifically focusing on oncology and radiology. Its technical architecture utilizes advanced deep learning and convolutional neural networks (CNNs) trained on massive, curated datasets of millions of medical images. The company offers two core product lines: Lunit INSIGHT, which focuses on chest X-rays (CXR) and mammography (MMG/DBT) to detect early-stage cancer and abnormalities with superhuman precision; and Lunit SCOPE, a breakthrough digital pathology platform that analyzes tissue slides to predict patient responses to immunotherapy. By 2026, Lunit has solidified its market position through the strategic acquisition of Volpara Health, expanding its reach into the US breast cancer screening market. Its systems are designed for high-throughput clinical environments, integrating directly with existing PACS and RIS infrastructure. Lunit's solutions are clinically validated in peer-reviewed journals, consistently demonstrating improved diagnostic sensitivity and a significant reduction in false positives, thereby optimizing workflow efficiency for radiologists and pathologists globally.